DA-JC4 is a compound with dual GLP-1/GIP receptor agonist properties. It is recommended for use in researching neurological diseases and investigating insulin signaling pathways[1][2][3].

DA-JC4 (1~100 nM; hippocampal cells) effectively prevents rotenone-induced hippocampal neuron death and significantly reduces the activation of Cyt C, Bax, and Caspases[3].

DA-JC4 (10 nmol/kg; i.p.; once daily for 14 days) significantly prevents spatial learning deficits in Y-maze and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus[1]. DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high expression levels of tyrosine hydroxylase in the substantia nigra and increases expression of the neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)[2]. DA-JC4 (50 nmol/kg; i.p.; once daily for 7 days) potentially improves Parkinson’s disease symptoms and enhances neurotransmission[3].